Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) SEC filings page provides access to the company’s regulatory disclosures as a public issuer. These documents include current reports on Form 8-K, periodic reports and other filings that describe clinical progress, material agreements, capital raises, governance changes and stockholder actions.
For investors tracking 4D Molecular Therapeutics’ gene therapy programs, Form 8-K filings are particularly relevant. Recent 8-Ks have covered topics such as interim clinical data from the PRISM Phase 1/2 trial of 4D-150 in wet age-related macular degeneration, updates on the AEROW trial of 4D-710 in cystic fibrosis lung disease, the collaboration and license agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets, and the appointment or transition of key executives and directors. Other 8-Ks report on equity offerings, preliminary cash and investment balances, and amendments to corporate bylaws.
Filings also disclose that 4D Molecular Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol FDMT, and they provide details on matters submitted to stockholder votes, such as director elections, auditor ratification and advisory votes on executive compensation and its frequency.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key terms of collaboration and license agreements, explain the implications of financing transactions, and surface important information about clinical data disclosures, governance changes and cash runway guidance. Users can also review filings that relate to equity offerings, including underwriting agreements and pre-funded warrants, and examine how these transactions fit into 4D Molecular Therapeutics’ overall development and funding strategy.
4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.
The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.
4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.
The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.
4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock. The options have an exercise price of $9.88 per share and expire on March 24, 2036.
According to the terms, 1/48 of the underlying shares will vest each month starting on March 25, 2026, so long as Simms remains a service provider, with full vesting on the fourth anniversary of that date. Following this grant, he holds options for 219,000 shares directly.
4D Molecular Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report separately.
4D Molecular Therapeutics VP Ashoo Gupta reported routine equity compensation activity. On March 20, 2026, Gupta exercised restricted stock units (RSUs) into 1,086 shares of common stock at a conversion price of $0.00 per share.
On the same date, 390 common shares were sold at $8.61 per share in an automatic “sell-to-cover” transaction to satisfy tax withholding obligations, as described in the footnotes, rather than a discretionary trade. Following these transactions, Gupta directly held 47,055 common shares, plus RSU awards that continue to vest beginning on June 20, 2025 in scheduled quarterly installments while serving as a company service provider.
4D Molecular Therapeutics describes a late-stage gene therapy pipeline focused on retinal and lung diseases. Lead candidate 4D-150, for wet age-related macular degeneration and diabetic macular edema, is in global Phase 3 trials with RMAT and PRIME designations and strong early data on reducing anti-VEGF injection burden.
The company is also advancing 4D-710 for cystic fibrosis lung disease, showing durable CFTR expression and early clinical activity in the AEROW Phase 1/2 trial, with Phase 2 dosing selected. As of June 30, 2025, non-affiliate equity was valued at $166,461,070, and as of March 16, 2026, 51,051,487 common shares were outstanding, with an additional 16,935,665 shares issuable upon exercise of pre-funded warrants.
4D Molecular Therapeutics reported full year 2025 results and highlighted major partnering and financing activities that support its late-stage gene therapy pipeline. Collaboration and license revenue rose to $85.2 million, mainly from an upfront payment under the Otsuka partnership, while net loss narrowed to $140.1 million from $160.9 million in 2024. Research and development expenses increased to $195.7 million, reflecting advancement of the 4D-150 Phase 3 wet AMD program and other trials. Cash, cash equivalents and marketable securities were $514.0 million as of December 31, 2025, which the company expects will fund its operating plan into the second half of 2028. The company also completed an additional $118 million in equity financings and reported positive interim data and upcoming milestones for 4D-150 in retinal diseases and 4D-710 for cystic fibrosis lung disease.
Novo Holdings A/S reported beneficial ownership of 3,650,737 shares of 4D Molecular Therapeutics common stock, representing 6.4% of the outstanding class as of the event date. Novo Holdings has sole power to vote and dispose of these shares, with no shared voting or dispositive power.
The filing states that the position was not acquired and is not held for the purpose of changing or influencing control of the company, indicating a passive investment intent under the Schedule 13G framework.
4D Molecular Therapeutics, Inc. received an updated Schedule 13G/A from RA Capital Management and related entities reporting a significant ownership stake. As of December 31, 2025, the reporting group beneficially owned 5,713,852 shares of common stock, representing 9.99% of the outstanding shares.
The RA Capital Healthcare Fund directly holds 5,653,211 shares of common stock and pre-funded warrants exercisable for up to 3,610,000 additional shares. These pre-funded warrants include a 9.99% "Beneficial Ownership Blocker," which currently limits exercisability so that beneficial ownership does not exceed 9.99% of the company’s common stock.
RA Capital, along with Peter Kolchinsky and Rajeev Shah, may be deemed beneficial owners through their control and advisory roles, but they expressly disclaim beneficial ownership except for Section 13(d) reporting purposes. The filing also certifies that the securities were not acquired to change or influence control of 4D Molecular Therapeutics.
4D Molecular Therapeutics, Inc. received an updated ownership report from a group of funds affiliated with Biotechnology Value Fund and investor Mark N. Lampert, detailing their passive stake in the company’s common stock.
As of December 31, 2025, the BVF funds and a managed account held Pre-Funded Warrants exercisable for an aggregate of 6,725,665 shares, at an exercise price of $0.0001 per share. A 9.99% ownership cap in these warrants limits how many can be exercised at any time, so only 1,217,992 underlying shares are currently counted as beneficially owned.
Based on the share count referenced from the company’s latest quarterly report and warrant exercises, BVF entities report significant positions: BVF at about 6.1% of outstanding shares, BVF II at about 3.1%, and Trading Fund OS at less than 1%. Aggregating across the complex, BVF Partners, BVF Inc. and Mr. Lampert may each be deemed to beneficially own approximately 9.99% of 4D Molecular’s outstanding common stock. The group certifies that the securities are not held for the purpose of changing or influencing control of the company.